Anna A. Dyatlova

Anna A. Dyatlova

Auto-generated profile, based on publicly available information

Anna A. Dyatlova

Stavropol State Medical University; Regional Children’s Clinical Hospital

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2021 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
IZIrina Zakharova
Irina Zakharova
MEMoscow Russian Medical Academy For Continuous Professional Education
Moscow Russian Medical Academy For Continuous Professional Education
LKL.Ya. Klimov
L.Ya. Klimov
AYA.V. Yagupova
A.V. Yagupova
VKV.A. Kuryaninova
V.A. Kuryaninova
AMA.K. Minasyan
A.K. Minasyan
To date, the most discussed issue is the rational dosage and duration of cholecalciferol preparations course for the correction and prevention of hypovitaminosis D. Objective of the research: to compare the structure of provision and the median 25 (OH) D before (2013–2016) and during the introduction into clinical practice (2018–2019) of the National Program Vitamin D Deficiency in Children and Adolescents in the Russian Federation: Modern approaches to correction» in young children. Materials and methods: the study had two stages. The first stage took place as a part of the RODNICHOK2 study from 2013 to 2016 before the implementation of the National Program «Vitamin D Deficiency in Children and Adolescents in the Russian Federation: Modern Approaches to Correction». The second stage of the study took place in 2018–2019 during the implementation of the National Program in clinical practice. The study participants were 246 children aged from 1 month to 3 years who took cholecalciferol preparations. The assessment of calcidiol concentration in the blood serum was assessed by the method of chemiluminescence immunoassay (CLIA) using reagents Liaison® 25OH Vitamin D Total Assay on the Liaison Dia Sorin Pleutschland GmbH device in the centralized laboratory of Scientific Center EFIS Ltd, Moscow. Results: during the introduction into clinical practice of the National Program, the frequency of prescribing a dosage of 500 IU/day significantly decreased to 4,9% (χ2=80,4, p

9 March 2020 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
IZIrina Zakharova
Irina Zakharova
ATA. N. Tsutsayeva
A. N. Tsutsayeva
LKL. Ya. Klimov
L. Ya. Klimov
VKV. A. Kur'YAninova
V. A. Kur'YAninova
SDS. V. Dolbnya
S. V. Dolbnya
RBRoman O. Budkevich
Roman O. Budkevich
Витамин D и продукция дефензинов у детей раннего возраста

27 July 2023 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Closed access
SDS. V. Dolbnya
S. V. Dolbnya
ADA. A. Dyatlova
A. A. Dyatlova
LKL. Ya. Klimov
L. Ya. Klimov
EKElena Kondatyeva
Elena Kondatyeva
IZIrina Zakharova
Irina Zakharova
EEE. A. Enina
E. A. Enina
Introduction. The role and mechanism of the effect of vitamin D on the course of chronic lung diseases in children are not yet fully understood. In particular, there are not enough studies on the effect of vitamin D status on the production of interferon-γ (IFN-γ) in children with cystic fibrosis and bronchial asthma.Aim. To analyse the changes in IFN-γ levels in children with cystic fibrosis and bronchial asthma according to the serum 25(OH)D level before and during cholecalciferol supplementation.Materials and methods. A total of 114 children (aged from 3 months to 18 years old) were examined, including 51 (44.7%) children with bronchial asthma, 34 (29.8%) children with cystic fibrosis, and 29 (25.5%) children of the control group. If hypovitaminosis D was diagnosed, the children received a three-month cholecalciferol course at doses in accordance with the recommendations of the national consensus - Cystic Fibrosis: Definition, Diagnostic Criteria, Therapy and the national program - Vitamin D Deficiency in Children and Adolescents of the Russian Federation: Current Approaches to Management. The 25(OH)D and IFN-γ levels were twice determined in all children.Results. Median 25(OH)D levels in patients with cystic fibrosis and bronchial asthma did not reach the level of healthy children either before or after supplementation with cholecalciferol drugs at the recommended doses. Vitamin D intake resulted in a decrease in IFN-γ levels in healthy children from 3.07 [2.29; 4.81] pg/ml to 2.18 [1.74; 3.45] pg/ml (p < 0.05), whereas such changes were not detected in the paediatric patients with cystic fibrosis and bronchial asthma in the general population. However, after supplementation with cholecalciferol, the IFN-γ level was significantly higher in patients with cystic fibrosis and bronchial asthma - 2.86 [2.13; 3.86] pg/ml and 3.11 [0.89; 5.0] pg/ml, respectively, than in healthy children - 2.18 [1.74; 3.45] pg/ml (p < 0.05). A statistically significant decrease in IFN-γ level was observed in girls with cystic fibrosis and in healthy girls after supplementation with cholecalciferol, whereas no significant changes in IFN-γ levels were detected in the groups of boys.Conclusion. Modulation of IFN-γ levels appears to be one of the mechanisms of immunotropic effect of vitamin D on the course of chronic inflammation of infectious (cystic fibrosis) and allergic (bronchial asthma) etiology in children.

29 July 2020 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
IZIrina Zakharova
Irina Zakharova
LKL. Ya. Klimov
L. Ya. Klimov
SDS. V. Dolbnya
S. V. Dolbnya
VKV. A. Kuryaninova
V. A. Kuryaninova
SMS. V. Maltsev
S. V. Maltsev
SKSh. O. Kipkeev
Sh. O. Kipkeev
Introduction. Vitamin D plays a fundamental role in the regulation of calcium and phosphorus homeostasis, and in recent decades its non-calcemic effects have been intensively studied.The aim of the work was to analyze the patterns of vitamin D availability in young children against the background of prolonged use of an aqueous solution of cholecalciferol in preventive doses.Materials and methods: 192 children of the first three years of life were examined (Arkhangelsk – 77 (40.1%), Moscow – 38 (19.8%), Stavropol – 77 (40.1%) children). Assessment of vitamin D availability was carried out by the level of serum calcidiol (25(OH)D). Based on the initial vitamin D supply, patients were divided into groups, and participants used cholecalciferol preparations for 30 days.Results. The baseline vitamin D supply was 26.0 (19.5–35.4) ng/ml. Median 25(OH)D in children in the Moscow region is higher than in Arkhangelsk and Stavropol (p<0.0001). After using vitamin D in therapeutic doses, the median 25 (OH) D in Arkhangelsk was 46.7 (32.3–64.5) ng/ml, in Moscow – 52.6 (40.2–64.9) ng/ml, in Stavropol – 51.4 (41.3–69.8) ng/ml. According to the results of taking the prophylactic dose (1000 IU/day), satisfactory vitamin D was detected in 105 (54.7%) patients, insufficiency (from 20 to 30 ng/ml) – in 70 (36.5%), deficiency (from 10 up to 20 ng/ml) – in 17 (8.8%) children. Among children who had a 25(OH)D level of more than 30 ng/ml at the end of the study, the use of vitamin D preparations of 50–100 IU/kg and in 42 (41.0%) was effective in 62 (59.0%) children – in a dose of 100–150 IU/day, and in the group of patients with a level of 25(OH)D less than 30 ng/ml – a dose of 50 to 100 IU/kg was used in 69 (79.3%) patients, and a dosage of 100–150 IU/kg in only 18 (20.7%) children (p < 0.0005).Conclusion. The used prophylactic dosage of 1000 IU/day of an aqueous solution of cholecalciferol was effective in most compliance children. The elimination of deficiency and the prevention of vitamin D deficiency is most effective when used for 6 months or more.

25 April 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
IPI. I. Pshenichnikova
I. I. Pshenichnikova
IZIrina Zakharova
Irina Zakharova
IBI. V. Berezhnaya
I. V. Berezhnaya
YKYu. V. Koba
Yu. V. Koba
ADA. A. Dyatlova
A. A. Dyatlova
The conditions of human development during the stages of early ontogenesis are of great importance for human health throughout the rest of his life. The period of intrauterine development and childhood are vulnerable stages of organism formation, when metabolic processes have the greatest plasticity and can be subject to deformation. Exposure to a number of external factors during this period of time can have a significant impact on the functional activity of genes controlling neurotransmission, immune response, endocrine functions and, thus, program the spectrum of metabolic disorders that can lead later to the formation of chronic diseases: obesity, type 2 diabetes, atherosclerosis and diseases of cardiovascular system. Negative programming influence on the metabolic profile and cardiovascular risk is caused by such factors as maternal obesity, complicated pregnancy and childbirth, prematurity, early separation from the mother, violation of child feeding in the 1st year of life. The risk of early development of cardiovascular disease, metabolic syndrome, obesity and diabetes mellitus is significantly increased in individuals who have experienced traumatic stressors during childhood associated with economic disadvantage of the family, parental divorce, neglect, abuse, parental neglect, sexual violence, death of parents, family members, close friends, bullying in the children's community. An in-depth study of this problem, along with the development and organization of measures for monitoring and prevention, in the long term can reduce the burden of chronic non-infectious diseases, improve quality of life, reduce disability, incapacitation and mortality in the adult population..

7 August 2024 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
SDS. V. Dolbnya
S. V. Dolbnya
ATA. A. Tolkunova
A. A. Tolkunova
IZIrina Zakharova
Irina Zakharova
VPV. R. Ponamaryova
V. R. Ponamaryova
LKL. Ya. Klimov
L. Ya. Klimov
EEE. A. Enina
E. A. Enina
Introduction. Currently, there are insufficient studies to demonstrate the effect of vitamin D status on the production of proinflammatory cytokines in children with allergic diseases, which precipitated this study.Aim. To analyse interferon-γ, interleukin-17A and 33 profiles in children with asthma according to serum calcidiol levels before and during cholecalciferol subsidies.Materials and methods. A total of 71 children aged 3 to 18 years were examined: 51 patients with asthma and 20 children in the control group. A 3-month cholecalciferol course at a prophylactic dose specified in the national program was prescribed to all children. 25(OH)D, interferon-γ, interleukin-17A and 33 levels were twice determined in the examined children.Results and discussion. Median 25(OH)D levels in patients with asthma did not reach the levels of healthy children either before or after cholecalciferol subsidies at prophylactic doses. Vitamin D intake led to a decrease in interferon-γ levels in healthy children from 3.07 [2.29; 4.81] pg/ml to 2.18 [1.74; 3.45] pg/ml (p < 0.05). In patients with asthma, such changes were not detected in the initial population, however, after cholecalciferol subsidies their interferon-γ levels were significantly higher than those in healthy children: 3.11 [0.89; 5.0] pg/ml and 2.18 [1.74; 3.45] pg/ml, respectively (p < 0.05). Assessment results of interleukin-17A levels in children with asthma showed that the median cytokine levels were significantly higher before the cholecalciferol subsidies than after them: 2.03 [0.1; 10.01] pg/ml and 0.96 [0.1; 12.87] pg/ml, respectively (p = 0.03). The median interleukin-17A levels in children with asthma were significantly higher than in healthy children, both before and during the cholecalciferol subsidies. The median interleukin-33 levels were significantly higher in children with asthma as compared to healthy children, both before and during vitamin D subsidies.Conclusion. Our results suggest that cholecalciferol has a modulatory effect on interferon-γ and interleukin-17A in patients with asthma. Interleukin-33 levels did not change significantly in children with asthma on cholecalciferol.